In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
Analysts say the drug could emerge as a potential competitor to Merck’s blockbuster immunotherapy Keytruda. Keytruda is ...
No, Keytruda isn’t a chemotherapy drug. It’s an immunotherapy drug. Chemotherapy is a type of cancer treatment that kills cancer cells or stops them from multiplying (making more cells).
Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...
versus first-line treatment with Keytruda (pembrolizumab) plus chemotherapy. Findings, demonstrated by the phase 2 PERLA ...
Medpage Today on MSN1d
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free SurvivalAdding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...
Last month, that drug posted data showing it topped the blockbuster Merck immunotherapy Keytruda in a head-to-head Phase 3 test. In patients with advanced cases of non-small cell lung cancer ...
LOUISVILLE, Ky. -- Large tumor size and high disease grade were associated with an increased risk of early cancer-related ...
Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...
Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Chemoradiotherapy has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback